Cargando…

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

BACKGROUND: RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) therapy, but many tumors containing wild-type RAS genes still d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Xiaona, Li, Yuyao, Li, Yue, Zhang, Xuemei, Shi, Jia, Feng, Hai, Yu, Zhuo, Gao, Yueqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655341/ https://www.ncbi.nlm.nih.gov/pubmed/37974093 http://dx.doi.org/10.1186/s12885-023-11600-z

Ejemplares similares

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2017)

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2018)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
por: Yuan, Zi-Xu, et al.
Publicado: (2013)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles
por: Lu, Xiaona, et al.
Publicado: (2023)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
por: Hsieh, Meng-Chiao, et al.
Publicado: (2018)

SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer
por: van Reesema, Lauren L. Siewertsz, et al.
Publicado: (2016)

Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis
por: Zhou, Mingyi, et al.
Publicado: (2016)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
por: Yasui, H., et al.
Publicado: (2023)

Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
por: Mao, C, et al.
Publicado: (2010)

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
por: Randon, Giovanni, et al.
Publicado: (2022)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
por: Shinozaki, Eiji, et al.
Publicado: (2017)

Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies
por: Popa, C, et al.
Publicado: (2012)

A novel association of pyroptosis-related gene signature with the prognosis of hepatocellular carcinoma
por: Li, Yuyao, et al.
Publicado: (2022)

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
por: Palmieri, Lola-Jade, et al.
Publicado: (2022)

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
por: Arikan, Rukiye, et al.
Publicado: (2023)

Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer
por: Deyati, Avisek, et al.
Publicado: (2015)

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
por: Dankner, Matthew, et al.
Publicado: (2018)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
por: Shinozaki, Eiji, et al.
Publicado: (2018)

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer
por: Dolatkhah, Roya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u5q7orp2pnld5og13ai7824j9v